Development of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry (HPLC-MS/MS) Method to Determine the Presence of Rivastigmine in Human Plasma in Clinical Studies of Comparative Pharmacokinetics

The basis for conducting bioequivalence studies is the determination of bioavailability active substance drug at its place action by establishing concentration in biological fluids using sensitive analytical techniques. bioanalytical technique used should provide reliable results which would lead to satisfactory level interpretation. To investigate rivastigmine preparations, an 8 times more method (compared data available literature) quantitative human blood plasma HPLC-MS/MS was developed. Rivastigmine extracted from precipitation proteins with acetonitrile. Chromatographic separation and internal standard carried out on a YMC Triart C18. 50×2.0 mm (1.9 µm) column gradient elution mode flow rate 0.5 ml/min. A 0.1% solution ammonium hydroxide acetonitrile were as mobile phases. lower limit 25 pg/ml.